

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SUN PHARMACEUTICAL INDUSTRIES LTD.  
and  
SUN PHARMACEUTICAL INDUSTRIES, INC.,

Petitioners

v.

NOVO NORDISK A/S,  
Patent Owner

---

Case IPR2024-00107  
Patent 10,335,462

---

**DECLARATION OF SAYEM OSMAN**

I, Sayem Osman, make the following Declaration pursuant to 28 U.S.C. § 1746:

1. I am a paralegal at the law firm of Groombridge, Wu, Baughman & Stone LLP.
2. I provide this Declaration in connection with the above-identified Patent Owner's Preliminary Response to the *Inter Partes* Review proceeding that is being requested at the U.S. Patent and Trademark Office by Petitioners under 35 U.S.C. §§ 311-319, 37 C.F.R. § 42. Unless otherwise stated, the facts stated in this Declaration are based on my personal knowledge.
3. EX2001 hereto is a true and correct copy of an excerpt of Defendants' Initial Invalidity Contentions Regarding to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-01040-CFC, (D. Del. Oct. 20, 2022) which I retrieved on June 29, 2023, as an attachment to an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. Other than excerpting the pages, striking through the confidentiality designation, and adding an exhibit label and page numbers to the bottom of all pages of EX2001, no other alterations have been made.
4. EX2002 hereto is a true and correct copy of Petition for *Inter Partes* Review of U.S. Patent No. 10,335,462, which I retrieved on January 24, 2024, from the United States Patent & Trademark Office's P-Tacts website

([https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=b\\_q1LLcUgnhslVIMU0tD9zkdxWsQEEBi-V1wQDdI\\_1YE-eov0D-4ToU](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=b_q1LLcUgnhslVIMU0tD9zkdxWsQEEBi-V1wQDdI_1YE-eov0D-4ToU)). An exhibit label and page numbers have been added to the bottom of all pages of EX2002 but no other alterations have been made.

5. EX2004 hereto is a true and correct copy of the Stipulation and Order Regarding Trial of the MPI Ozempic Litigation, *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-03038, Dkt. 245 (D. Del. Oct. 31, 2023) which I retrieved on February 13, 2024, from <https://ecf.ded.uscourts.gov/doc1/04316204171>. Other than adding an exhibit label and page numbers to the bottom of all pages of EX2004, no other alterations have been made.

6. EX2005 hereto is a true and correct copy of an email from E. Goldschlager to Counsel dated Nov. 29, 2023 re: IPR2023-00724 Request for Conference Call. I received this email on Nov. 29, 2023 as a member of an email distribution group. An exhibit label and page numbers have been added to the bottom of all pages of EX2005 but no other alterations have been made.

7. EX2006 hereto is a true and correct copy of the Scheduling & Consolidation Order, *Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc.*, No. 1:22-cv-00294, Dkt. 22 (D. Del. June 30, 2023) which I retrieved on January 24, 2024, from [https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-cv-](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-cv-)

[00294/Novo\\_Nordisk\\_Inc.\\_et\\_al\\_v.\\_Rio\\_Biopharmaceuticals\\_Inc.\\_et\\_al/22/](#). An exhibit label and page numbers have been added to the bottom of all pages of EX2006 but no other alterations have been made.

8. EX2007 hereto is a true and correct copy of an excerpt of a Hearing Transcript of Dec. 13, 2023 Claim Construction Hearing, *Novo Nordisk Inc. v. Mylan Pharmaceuticals Inc.*, No. 23-101-CFC (D. Del. Dec. 13, 2023), which I understand was received by Novo Nordisk's counsel Groombridge, Wu, Baughman & Stone. An exhibit label and page numbers have been added to the bottom of all pages of EX2007 but no other alterations have been made.

9. EX2008 hereto is a true and correct copy of the Claim Construction Order, *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-03038, Dkt. 148 (D. Del. July 25, 2023) which I retrieved on February 13, 2024 from <https://ecf.ded.uscourts.gov/doc1/04316099431>. Other than adding an exhibit label and page numbers to the bottom of all pages of EX2008, no other alterations have been made.

10. EX2009 hereto is a true and correct copy of the Joint Stipulation and Order Amending Scheduling Order, *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-03038-CFC, Dkt. 268 (D. Del. Dec. 1, 2023), which I retrieved on January 24, 2024, from [https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-md-](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-md-)

[03038/In\\_Re--\\_Ozempic\\_%28Semaglutide%29\\_Patent\\_Litigation/268/](#). An exhibit

label and page numbers have been added to the bottom of all pages of EX2009 but no other alterations have been made.

11. EX2010 hereto is a true and correct copy of an excerpt of Novo Nordisk's Third Amended Disclosures to Defendants Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc., *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC (D. Del. July 28, 2023), which I received on February 2, 2024, as an attachment to an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. Other than striking through the confidentiality designation, and adding an exhibit label and page numbers to the bottom of all pages of EX2010, no other alterations have been made.

12. EX2011 hereto is a true and correct copy of United States Patent No. 8,114,833 which I retrieved on January 24, 2024, from the United States Patent & Trademark Office's Patent Public Search Basic (PPUBS Basic) website (<https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8114833>). An exhibit label and page numbers have been added to the bottom of all pages of EX2011 but no other alterations have been made.

13. EX2012 hereto is a true and correct copy of the Summons in a Civil Action, Sun Pharmaceutical Industries, Inc., Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd., No. 1:22-cv-00296-CFC, Dkt. 7 (D. Del. Mar. 7, 2022), which I

retrieved on February 9, 2024 from

[https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-cv-00296/Novo\\_Nordisk\\_A-S\\_et\\_al\\_v.\\_Sun\\_Pharmaceutical\\_Industries\\_Ltd.\\_et\\_al/7/](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-cv-00296/Novo_Nordisk_A-S_et_al_v._Sun_Pharmaceutical_Industries_Ltd._et_al/7/).

An exhibit label and page numbers have been added to the bottom of all pages of EX2012 but no other alterations have been made.

14. EX2013 hereto is a true and correct copy of the Summons in a Civil Action, Sun Pharmaceutical Industries Ltd., Novo Nordisk Inc. v. Sun Pharmaceutical Indus. Ltd., No. 1:22-cv-00296-CFC, Dkt. 8 (D. Del. Mar. 16, 2022), which I retrieved on February 9, 2024 from

[https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-cv-00296/Novo\\_Nordisk\\_A-S\\_et\\_al\\_v.\\_Sun\\_Pharmaceutical\\_Industries\\_Ltd.\\_et\\_al/8/](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-cv-00296/Novo_Nordisk_A-S_et_al_v._Sun_Pharmaceutical_Industries_Ltd._et_al/8/).

An exhibit label and page numbers have been added to the bottom of all pages of EX2013 but no other alterations have been made.

15. EX2014 hereto is a true and correct copy of an excerpt of the Redacted Patent Owner's Response, *Mylan Pharms. Inc. v. Novo Nordisk A/S*, IPR2023-00724, Pap.30 (Jan. 17, 2023), which I retrieved on January 25, 2024 from

[https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=YsEnVu4ftxcTMQcC5gGzzywFkHUzJXnYgM-](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=YsEnVu4ftxcTMQcC5gGzzywFkHUzJXnYgM-hMM3wNUu6AQSipaedcJ4)

[hMM3wNUu6AQSipaedcJ4](https://ptacts.uspto.gov/ptacts/public-informations/petitions/1553774/download-documents?artifactId=YsEnVu4ftxcTMQcC5gGzzywFkHUzJXnYgM-hMM3wNUu6AQSipaedcJ4). An exhibit label and page numbers have been added to the bottom of all pages of EX2014 but no other alterations have been made.

16. EX2015 hereto is a true and correct copy of an excerpt of Novo Nordisk's Initial Responses to Defendants' Initial Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343; 8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-01040-CFC, (D. Del. Dec. 21, 2022) [REDACTED], which I understand was received by counsel at Groombridge, Wu, Baughman & Stone from counsel at Fenwick & West on January 24, 2023, and which I received from counsel at Groombridge, Wu, Baughman & Stone on June 29, 2023. Other than excerpting the pages, striking through the confidentiality designation, and adding an exhibit label and page numbers to the bottom of all pages of EX2015, no other alterations have been made.

17. EX2016 hereto is a true and correct copy of the Transfer Order, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC, Dkt. 1 (D. Del. Aug. 5, 2022), which I retrieved on January 26, 2024 from [https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-md-03038/In\\_Re--\\_Ozempic\\_%28Semaglutide%29\\_Patent\\_Litigation/1/](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-md-03038/In_Re--_Ozempic_%28Semaglutide%29_Patent_Litigation/1/). An exhibit label and page numbers have been added to the bottom of all pages of EX2016 but no other alterations have been made.

18. EX2018 hereto is a true and correct copy of an excerpt of Defendants' Second Supplemental Invalidity Contentions Regarding U.S. Patent Nos. 8,129,343;

8,536,122; 8,114,833; 8,920,383; 9,775,953; 9,457,154; and 10,335,462, *In re:*

*Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC (D. Del. Jan. 12, 2024) [REDACTED], which I received on January 30, 2024, as an attachment to an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. Other than excerpting the pages, striking through the confidentiality designation, and adding an exhibit label and page numbers to the bottom of all pages of EX2018, no other alterations have been made.

19. EX2019 hereto is a true and correct copy of Novo Nordisk Production Letter, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC (D. Del. Oct. 17, 2023), *In re: Ozempic (Semaglutide) Patent Litigation*, No. 1:22-cv-01040-CFC, (D. Del. Dec. 21, 2022), which I received on January 26, 2024, as an attachment to an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. An exhibit label and page numbers have been added to the bottom of all pages of EX2019 but no other alterations have been made.

20. EX2020 hereto is a true and correct copy of a Compilation of Defendants' Production Letters, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC (D. Del.), which I received on January 26, 2024, as an attachment to an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. Other than compiling the pages and adding an exhibit label and page numbers to the bottom of all pages of EX2020, no other alterations have been made.

21. EX2021 hereto is a true and correct copy of a Compilation of Rule 30(b)(1) Deposition Notices, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC (D. Del.), which I received on January 26, 2024, as an attachment to an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. Other than compiling the pages and adding an exhibit label and page numbers to the bottom of all pages of EX2021, no other alterations have been made.

22. EX2022 hereto is a true and correct copy of the Notice of Service for Defendants' Initial Invalidity Contentions, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC, Dkt. 43 (D. Del. Oct. 20, 2022), which I retrieved on January 26, 2024 from

[https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-md-03038/In\\_Re--\\_Ozempic\\_%28Semaglutide%29\\_Patent\\_Litigation/43/](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-md-03038/In_Re--_Ozempic_%28Semaglutide%29_Patent_Litigation/43/). An exhibit label and page numbers have been added to the bottom of all pages of EX2022 but no other alterations have been made.

23. EX2023 hereto is a true and correct copy of the Notice of Service for Defendants' Supplemental Invalidity Contentions, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC, Dkt. 256 (D. Del. Nov. 6, 2023), which I retrieved on January 26, 2024 from

[https://www.docketalarm.com/cases/Delaware\\_District\\_Court/1--22-md-03038/In\\_Re--\\_Ozempic\\_%28Semaglutide%29\\_Patent\\_Litigation/256/](https://www.docketalarm.com/cases/Delaware_District_Court/1--22-md-03038/In_Re--_Ozempic_%28Semaglutide%29_Patent_Litigation/256/). An exhibit

label and page numbers have been added to the bottom of all pages of EX2023 but no other alterations have been made.

24. EX2024 hereto is a true and correct copy of the Stipulation for Extension of Time, *In re: Ozempic (Semaglutide) Patent Litigation*, MDL No. 22-MD-03038-CFC, Dkt. 309 (D. Del. Feb. 9, 2024), which I retrieved on February 28, 2024, from <https://ecf.ded.uscourts.gov/doc1/04316319072>. An exhibit label and page numbers have been added to the bottom of all pages of EX2024 but no other alterations have been made.

25. EX2025 hereto is a true and correct copy of an email from C. Ferenc (Novo Nordisk A/S's counsel at Fenwick & West LLP) to M. Raymond and the "Novo-Semaglutide-IPR" distribution list which I am part of, dated on February 26, 2024, and which I received on February 26, 2024. An exhibit label and page numbers have been added to the bottom of all pages of EX2025 but no other alterations have been made.

26. EX2026 hereto is a true and correct copy of Sun Pharmaceutical Industries Ltd.'s Stipulation of Invalidity Contentions *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-cv-00294-CFC, Dkt. 275 (D. Del. Nov. 6, 2023), which I received on February 26, 2024, as an attachment to EX2025, an email from Novo Nordisk A/S's counsel at Fenwick & West LLP. An exhibit label and page

numbers have been added to the bottom of all pages of EX2026 but no other alterations have been made.

27. EX2027 hereto is a true and correct copy of the Joint Stipulation and Order Extending Deadline for Certain Fact Discovery, *In re: Ozempic (Semaglutide) Patent Litigation*, No. 22-MD-03038-CFC, Dkt. 305 (D. Del. Feb. 6, 2024), which I retrieved on February 29, 2024, from [https://ecf.ded.uscourts.gov/cgi-bin/HistDocQry.pl?138188477641683-L\\_1\\_0-1](https://ecf.ded.uscourts.gov/cgi-bin/HistDocQry.pl?138188477641683-L_1_0-1). An exhibit label and page numbers have been added to the bottom of all pages of EX2027 but no other alterations have been made.

28. I have been warned that willful false statements and the like are punishable by fine or imprisonment, or both. I make this declaration of my own personal knowledge, and all statements are true. If called to testify as to the truth of the matters stated herein, I could and would testify competently.

29. I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct. Executed on this 29th day of February, 2026, at Addis Ababa, Ethiopia.

/Sayem Osman/  
Sayem Osman